| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA951: Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer |
|
Medicine details |
|
| Medicine name | olaparib (Lynparza®) |
| Formulation | tablet |
| Reference number | 4514 |
| Indication | In combination with abiraterone for treatment of 1L mCRPC (all-comers) |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/12/23 |
| NICE guidance | TA951: Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer |